CSF3 and cirrhosis of liver: This study can be contrasted with another phase 2 randomized controlled trial of cell therapy for liver cirrhosis (the REALISTIC study), with MELD scores in the range of 11–15.5 (ref. 15), that compared standard medical care (control) versus granulocyte colony-stimulating factor (G-CSF) alone versus G-CSF followed by leukapheresis and intravenous infusion of three doses of CD133+ hematopoietic stem cells.